For the Inventor, By the Inventor

Enter assignee name

Berlin, Germany

Silence Therapeutics Gmbh

USPTO Granted Patents = 37

CIPO Patents = 5

EPO Patents = 13

Trademarks = 4

Forward Citations = 190

Loading Chart...

Loading Chart...

25 inventors (with patents filed for the assignee):

Jörg Kaufmann (20 out of 32 patents)

Christian Frauendorf (12 out of 12 patents)

Klaus Giese (12 out of 27 patents)

4. Anke Klippel-Giese (12 out of 17 patents)

5. Judith Hauptmann (10 out of 10 patents)

6. Adrien Weingärtner (9 out of 9 patents)

7. Lucas Bethge (9 out of 12 patents)

8. Ansgar Santel (6 out of 9 patents)

9. Dmitry Samarsky (5 out of 5 patents)

10. Sibylle Dames (5 out of 5 patents)

11. Oliver Keil (5 out of 13 patents)

12. Stephan Tenbaum (3 out of 3 patents)

13. Steffen Schubert (3 out of 3 patents)

14. Ute Schaeper (3 out of 3 patents)

15. Alison Gallafent (2 out of 2 patents)

37 patents: Sort by Forward Citations

1. 12084656 - Products and compositions (2024-09-10),

2. 12076335 - Nucleic acids for inhibiting expression of TMPRSS6 and iron chelators (2024-09-03),

3. 12054717 - Nucleic acids for inhibiting expression of LPA in a cell (2024-08-06),

4. 11987794 - Products and compositions (2024-05-21),

5. 11912993 - Nucleic acid linked to a trivalent glycoconjugate (2024-02-27),

6. 11873489 - Nucleic acids for inhibiting expression of a target gene comprising phosphorodithioate linkages (2024-01-16),

7. 11820971 - Nucleic acids for inhibiting expression of PROS1 in a cell (2023-11-21),

8. 11753642 - Nucleic acids for inhibiting expression of C3 in a cell (2023-09-12),

9. 11578328 - Interfering RNA molecules (2023-02-14),

10. 11560563 - SiRNAs with vinylphosphonate at the 5' end of the antisense strand (2023-01-24),

11. 11499153 - Nucleic acids for inhibiting expression of LPA in a cell (2022-11-15),

12. 11414660 - Products and compositions (2022-08-16),

13. 11319537 - Nucleic acids for inhibiting expression of LPA in a cell (2022-05-03),

14. 11299738 - Further novel oligonucleotide-ligand conjugates (2022-04-12),

15. 11174483 - Products and compositions (2021-11-16),

Silence Therapeutics GmbH is a leading RNAi therapeutics company focused on discovering, developing, and delivering innovative medicines to treat a wide range of diseases. The company utilizes its proprietary technology platform to enable specific gene silencing through RNA interference (RNAi). By harnessing the power of RNAi, Silence Therapeutics aims to develop breakthrough therapies that have the potential to transform the lives of patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

37 Patents

#29 in D-1000 Berlin

#1,389 in Germany

#17,726 in the World

Berlin, Germany

Silence Therapeutics Gmbh

Forward Citations = 190

25 inventors:

Jörg Kaufmann (20 out of 32 patents)

Christian Frauendorf (12 out of 12 patents)

Klaus Giese (12 out of 27 patents)

4. Anke Klippel-Giese (12 out of 17 patents)

5. Judith Hauptmann (10 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…